Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency
Beth A. Bouchard, John C. Chapin, Kathleen E. Brummel‐Ziedins et al. · Blood · 2015
Whole genome sequencing of an individual completely devoid of plasma- and platelet-derived factor V (FV) identified 167 variants in his F5 gene including previously identified and damaging missense mutations at rs6027 and Leu90Ser. Because the administration of fresh frozen plasma (FFP) prevents gastrointestinal bleeding in this individual, its effects on his plasma- and platelet-derived FV concentrations were assessed. The patient's plasma FV levels peaked by 2 hours following FFP administration and were undetectable 96 hours later. In contrast, increased platelet-derived FV/Va concentrations were observed within 6 hours, peaked at 24 hours, decreased slowly over 7 days, and originated from megakaryocyte endocytosis and intracellular processing of plasma FV. Ten days after transfusion, no thrombin was generated in a tissue factor-initiated whole blood clotting assay unless exogenous FV was added, consistent with the complete absence of plasma FV. In marked contrast, release of the patient's platelet-derived FV/Va (7% of normal) following platelet activation resulted in robust thrombin generation, similar to that in an individual with normal plasma- and platelet-derived FV concentrations. Thus, total FV deficiency can be corrected by plasma administration, which partially repletes and sustains the platelet cofactor pool, thereby highlighting the critical role of platelet-derived FV/Va in ensuring hemostatic competence.
Cited by 52 works. doi:10.1182/blood-2014-07-589580
Authors
References
- The Hemostatic Effect of Normal Platelets in Hemophilia and factor V Deficiency
- Thrombin functions during tissue factor–induced blood coagulation
- Radioimmunoassay of factor V in human plasma and platelets
- Isolation and study of an acquired inhibitor of human coagulation factor V.
- Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions
- Symptoms of inherited factor V deficiency in 35 Iranian patients
- Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin.
- Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms
- Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency
- The Mechanism of Inactivation of Human Platelet Factor Va from Normal and Activated Protein C-resistant Individuals